List of Merrimack Pharmaceuticals patents

Patents where

Current Assignee

Name

Merrimack Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9982060 Bi-specific fusion proteins	Patent 9982060 was granted and assigned to Merrimack Pharmaceuticals on May, 2018 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9982060	May 29, 2018
‌ US Patent 9718892 Method of treating myocardial infarction by administering a bi-specific fusion protein	Patent 9718892 was granted and assigned to Merrimack Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9718892	August 1, 2017
‌ US Patent 8691771 Bi-specific fusion proteins for tissue repair	Patent 8691771 was granted and assigned to Merrimack Pharmaceuticals on April, 2014 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	8691771	April 8, 2014
‌ US Patent 9238080 Bi-specific fusion proteins	Patent 9238080 was granted and assigned to Merrimack Pharmaceuticals on January, 2016 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	9238080	January 19, 2016
‌ US Patent 7846440 Antibodies against ErbB3 and uses thereof	Patent 7846440 was granted and assigned to Merrimack Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	7846440	December 7, 2010
‌ US Patent 9044460 Antibodies against epidermal growth factor receptor (EGFR) and uses thereof	Patent 9044460 was granted and assigned to Merrimack Pharmaceuticals on June, 2015 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	9044460	June 2, 2015
‌ US Patent 10087464 Compositions and methods for delivering nucleic acid to a cell	Patent 10087464 was granted and assigned to Merrimack Pharmaceuticals on October, 2018 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	10087464	October 2, 2018
‌ US Patent 9226964 Antibodies against epidermal growth factor receptor (EGFR) and uses thereof	Patent 9226964 was granted and assigned to Merrimack Pharmaceuticals on January, 2016 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9226964	January 5, 2016
‌ US Patent 9452162 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Patent 9452162 was granted and assigned to Merrimack Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9452162	September 27, 2016
‌ US Patent 10273304 Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies	Patent 10273304 was granted and assigned to Merrimack Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	10273304	April 30, 2019
‌ US Patent 9556274 Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies	Patent 9556274 was granted and assigned to Merrimack Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9556274	January 31, 2017
‌ US Patent 9364473 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Patent 9364473 was granted and assigned to Merrimack Pharmaceuticals on June, 2016 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9364473	June 14, 2016
‌ US Patent 9968694 Compositions and methods for non-invasive imaging	Patent 9968694 was granted and assigned to Merrimack Pharmaceuticals on May, 2018 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9968694	May 15, 2018
‌ US Patent 8476409 Bispecific anti-IGF-1R and anti-ErbB3 antibodies	Patent 8476409 was granted and assigned to Merrimack Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	8476409	July 2, 2013
‌ US Patent 10570119 Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)	Patent 10570119 was granted and assigned to Merrimack Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	10570119	February 25, 2020
‌ US Patent 9226966 Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents	Patent 9226966 was granted and assigned to Merrimack Pharmaceuticals on January, 2016 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9226966	January 5, 2016
‌ US Patent 9610249 Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents	Patent 9610249 was granted and assigned to Merrimack Pharmaceuticals on April, 2017 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9610249	April 4, 2017
‌ US Patent 9938346 Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies	Patent 9938346 was granted and assigned to Merrimack Pharmaceuticals on April, 2018 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9938346	April 10, 2018
‌ US Patent 8623592 Methods and systems for predicting response of cells to a therapeutic agent	Patent 8623592 was granted and assigned to Merrimack Pharmaceuticals on January, 2014 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	8623592	January 7, 2014
‌ US Patent 9913901 Combination therapy for treating HER2-positive cancers	Patent 9913901 was granted and assigned to Merrimack Pharmaceuticals on March, 2018 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9913901	March 13, 2018
‌ US Patent 7208576 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof	Patent 7208576 was granted and assigned to Merrimack Pharmaceuticals on April, 2007 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	7208576	April 24, 2007
‌ US Patent 8961966 Antibodies against ERBB3 and uses thereof	Patent 8961966 was granted and assigned to Merrimack Pharmaceuticals on February, 2015 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	8961966	February 24, 2015
‌ US Patent 8691225 Antibodies against the ectodomain of ErbB3 and uses thereof	Patent 8691225 was granted and assigned to Merrimack Pharmaceuticals on April, 2014 by the United States Patent and Trademark Office.		Merrimack Pharmaceuticals	United States Patent and Trademark Office	8691225	April 8, 2014
‌ US Patent 8992970 Liposomes useful for drug delivery	Patent 8992970 was granted and assigned to Merrimack Pharmaceuticals on March, 2015 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	8992970	March 31, 2015
‌ US Patent 9345766 Combination therapies comprising anti-ERBB3 agents	Patent 9345766 was granted and assigned to Merrimack Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	United States Patent and Trademark Office	9345766	May 24, 2016

Results per page:

50 results

0 selected

50 results

0 selected